Fig. 6: Bispecificity demonstrated by bridging sandwich ELISA.

Bispecific anti-ocrelizumab/anti-dupilumab antibodies were produced according to the rapid or purity protocol and their serial dilutions were tested in bridging sandwich ELISA in which antigens dupilumab or ocrelizumab were coated on the plate and HRP-labeled form of either of both antigens was used for detection. A Schematic representation of the assay. B ELISA assay to detect bispecific antibodies. Left: ocrelizumab coated. Right: dupilumab coated. Monospecific bivalent controls constructed with BiCatcher3 were also tested with both HRP-labeled antigens. Coating antigen: 1 µg/mL, sandwich titration in 1:2 dilution series starting from 150 nM, HRP-labeled detection antigen: 2 µg/mL. Measurements performed independently in triplicates with the exception of non-cognate background controls, for which only one measurement was performed. Logistic fits were applied; error bars represent standard deviations, points represent the mean of measurements. Source data are provided as a Source Data file.